Brief: Iveric Bio Announces Vision Loss Reduction Data In Geographic Atrophy From Avacincaptad Pegol Gather Trials
01/03/2023 11:43
March 1 (Reuters) - IVERIC bio Inc ISEE.O :
* IVERIC BIO ANNOUNCES VISION LOSS REDUCTION DATA IN
GEOGRAPHIC
ATROPHY FROM AVACINCAPTAD PEGOL GATHER TRIALS
* POST-HOC TIME-TO-EVENT ANALYSIS SIGNALS UP TO 59% RISK
REDUCTION
IN RATE OF VISION LOSS COMPARED TO SHAM TREATMENT AT 12 MONTHS
* RESULTS WERE CONSISTENT IN GATHER1 AND GATHER2 CLINICAL
TRIALS
INDEPENDENTLY
Source text for Eikon: ID:nBw1FR4Mxa
Further company coverage: ISEE.O
Recent news on IVERIC bio
See all newsBrief: Astellas Pharma Inc - Astellas Completes Acquisition Of Iveric Bio
Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
Iveric Bio Inc Reports Results For The Quarter Ended In March: Earnings Summary
The end of cheap credit could hurry Japanese M&A
U.S. STOCKS ON THE MOVE-US banks, Biomea Fusion, Tutor Perini